LEAP2 and obesity disorder: Surprisingly, in the present study, there was no decrease in postprandial increases in plasma LEAP2 with weight loss and improved glycemic/metabolic control from LCD and increased physical activity–induced weight loss in obesity and T2DM over 2 years in the SMM group; however, this was examined only in a smaller subset of the cohort.